Vertex Pharmaceuticals Aktie 983327 / US92532F1003
462.11
USD
3.01
USD
0.66%
21:59:52
BTT
| Kurse + Charts + Realtime | News + Analysen | Fundamental | Unternehmen | zugeh. Wertpapiere | Aktion | |
|---|---|---|---|---|---|---|
| Kurs + Chart | Chart (gross) | News + Adhoc | Bilanz/GuV | Termine | Strukturierte Produkte | Portfolio |
| Times + Sales | Chartvergleich | Analysen | Schätzungen | Profil | Watchlist | |
| Börsenplätze | Realtime Push | Kursziele | Dividende/GV | |||
| Orderbuch | Analysen | |||||
| Historisch | ||||||
Kurse + Charts + Realtime
News + Analysen
Fundamental
zugeh. Wertpapiere
Vertex Pharmaceuticals Dividenden Kalender
| Datum | Name | Rendite * | Dividende | Währung |
|---|---|---|---|---|
| 2024 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2023 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2022 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2021 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2020 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2019 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2018 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2017 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2016 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
| 2015 | Vertex Pharmaceuticals Inc. | 0.00 | 0.00 | USD |
Gewinn je Aktie- Vertex Pharmaceuticals
| -2.1 24 | 13.9 23 | 12.8 22 | 9.0 21 | 10.3 20 | 4.5 19 | 8.1 18 |
Umsatz je Aktie- Vertex Pharmaceuticals
| 42.6 24 | 37.8 23 | 33.8 22 | 29.3 21 | 23.6 20 | 15.8 19 | 11.8 18 |
KGV- Vertex Pharmaceuticals
| 29.3 23 | 22.5 22 | 24.4 21 | 23.0 20 | 48.5 19 | 20.5 18 |
Vertex Pharmaceuticals Inc.: Die Aktie (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie berichtet | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 |
| Gewinn je Aktie unverwässert | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.24 |
| Gewinn je Aktie verwässert | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 |
| Dividende pro Aktie | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gesamtdividendenausschüttung in Mio. | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Vertex Pharmaceuticals Inc.: Unternehmenskennzahlen (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatz je Aktie | 42.59 | 37.77 | 33.76 | 29.26 | 23.57 | 15.84 | 11.76 |
| KGV (Jahresendkurs, EPS unverwässert) | - | 29.28 | 22.52 | 24.37 | 22.96 | 48.50 | 20.48 |
| KGV (Jahresendkurs, EPS verwässert) | - | 29.28 | 22.52 | 24.37 | 22.96 | 48.50 | 20.48 |
| Dividendenrendite Jahresende in % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Eigenkapitalquote in % | 71.07 | 76.15 | 76.65 | 75.19 | 73.92 | 73.15 | 71.01 |
| Fremdkapitalquote in % | 28.93 | 23.85 | 23.35 | 24.81 | 26.08 | 26.85 | 28.99 |
Vertex Pharmaceuticals Inc.: GuV (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Umsatzerlöse | 10’984.40 | 9’839.00 | 8’748.20 | 7’604.40 | 6’209.40 | 4’130.28 | 3’048.85 |
| Umsatzveränderung in % | 11.64 | 12.47 | 15.04 | 22.47 | 50.34 | 35.47 | 22.51 |
| Bruttoergebnis vom Umsatz | 9’453.90 | 8’576.80 | 7’667.90 | 6’700.20 | 5’473.10 | 3’582.52 | 2’639.31 |
| Bruttoergebnisveränderung in % | 10.23 | 11.85 | 14.44 | 22.42 | 52.77 | 35.74 | 19.24 |
| Operatives Ergebnis | 4’359.30 | 4’277.30 | 4’080.40 | 2’809.00 | 2’873.10 | 1’169.48 | 665.22 |
| Veränderung Operatives Ergebnis in % | 1.92 | 4.83 | 45.26 | -2.23 | 145.67 | 75.80 | 67.17 |
| Ergebnis vor Steuern | 248.50 | 4’379.80 | 4’232.40 | 2’730.40 | 3’116.80 | 1’394.92 | 600.24 |
| Veränderung Ergebnis vor Steuern in % | -94.33 | 3.48 | 55.01 | -12.40 | 123.44 | 132.39 | - |
| Ergebnis nach Steuer | -535.60 | 3’619.60 | 3’322.00 | 2’342.10 | 2’711.65 | 1’176.81 | 2’096.40 |
| Veränderung Ergebnis nach Steuer in % | - | 8.96 | 41.84 | -13.63 | 130.42 | -43.87 | 696.53 |
Vertex Pharmaceuticals Inc.: Bilanz (in Mio. USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gesamtverbindlichkeiten | 6’681 | 5’506 | 4’238 | 3’333 | 3’065 | 2’233 | 1’811 |
| Langzeit Gesamtverbindlichk. pro Aktie | 12.13 | 7.60 | 5.82 | 4.68 | 4.57 | 3.47 | 2.71 |
| Eigenkapital | 16’410 | 17’580 | 13’913 | 10’100 | 8’687 | 6’085 | 4’435 |
| Veränderung Eigenkapital in % | -6.66 | 26.36 | 37.75 | 16.27 | 42.75 | 37.20 | 118.64 |
| Bilanzsumme | 23’091 | 23’086 | 18’151 | 13’433 | 11’752 | 8’318 | 6’246 |
| Veränderung Bilanzsumme in % | 0.02 | 27.19 | 35.13 | 14.30 | 41.27 | 33.18 | 76.14 |
Vertex Pharmaceuticals Inc.: Sonstige Angaben (in USD)
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Gewinn je Aktie (unverwässert) | -2.08 | 14.05 | 12.97 | 9.09 | 10.44 | 4.58 | 8.24 |
| Veränderung Gewinn je Aktie (unverwässert) in % | -114.79 | 8.28 | 42.72 | -12.91 | 127.66 | -44.37 | 677.36 |
| Gewinn je Aktie (verwässert) | -2.08 | 13.89 | 12.82 | 9.01 | 10.29 | 4.51 | 8.09 |
| Veränderung Gewinn je Aktie (verwässert) in % | -114.95 | 8.37 | 42.28 | -12.47 | 128.04 | -44.20 | 677.88 |
| Anzahl Mitarbeiter | 6’100 | 5’400 | 4’800 | 3’900 | 3’400 | 3’000 | 2’500 |
| Veränderung Anzahl Mitarbeiter in % | 12.96 | 12.50 | 23.08 | 14.71 | 13.33 | 20.00 | 8.70 |
Vertex Pharmaceuticals Inc. Termine
| Unternehmen | Event | Datum |
|---|---|---|
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 30.04.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 31.07.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 29.10.2025 |
| Vertex Pharmaceuticals Inc. | Quartalszahlen | 04.02.2026 |
Vertex Pharmaceuticals Inc. vergangene Termine
| Terminart | Info | Datum |
|---|---|---|
| Quartalszahlen | Q4 2024 Earnings Release | 10.02.2025 |
| Quartalszahlen | Q3 2024 Earnings Release | 04.11.2024 |
| Quartalszahlen | Q2 2024 Earnings Release | 01.08.2024 |
| Hauptversammlung | Annual General Meeting | 15.05.2024 |
| Quartalszahlen | Q1 2024 Earnings Release | 06.05.2024 |
| Quartalszahlen | Q4 2023 Earnings Release | 05.02.2024 |
| Quartalszahlen | Q3 2023 Earnings Release | 06.11.2023 |
| Quartalszahlen | Q2 2023 Earnings Release | 01.08.2023 |
| Hauptversammlung | Annual General Meeting | 17.05.2023 |
| Quartalszahlen | Q1 2023 Earnings Release | 01.05.2023 |
| Quartalszahlen | Q4 2022 Earnings Release | 07.02.2023 |
| Quartalszahlen | Q3 2022 Earnings Release | 27.10.2022 |
| Quartalszahlen | Q2 2022 Earnings Release | 04.08.2022 |
| Hauptversammlung | Annual General Meeting | 18.05.2022 |
| Quartalszahlen | Q1 2022 Earnings Release | 05.05.2022 |
| Quartalszahlen | Q4 2021 Earnings Release | 26.01.2022 |
Personal
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 2’500 | 3’000 | 3’400 | 3’900 | 4’800 |
| Umsatz pro Mitarbeiter in Mio. EUR | 1.22 | 1.38 | 1.83 | 1.95 | 1.82 |
Bilanz (in Mio. USD) - Aktiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 3’843 | 4’823 | 8’133 | 9’561 | 13’235 |
| Summe Anlagevermögen | 2’403 | 3’496 | 3’618 | 3’872 | 4’916 |
| Summe Aktiva | 6’246 | 8’318 | 11’752 | 13’433 | 18’151 |
Bilanz (in Mio. USD) - Passiva
| 2018 | 2019 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 1’811 | 2’233 | 3’065 | 3’333 | 4’238 |
| Summe Eigenkapital | 4’435 | 6’085 | 8’687 | 10’100 | 13’913 |
| Summe Passiva | 6’246 | 8’318 | 11’752 | 13’433 | 18’151 |
Adresse
| 50 Northern Avenue, 02210 Boston | |
| Telefon | +1 (617) 341-6100 |
| URL | http://www.vrtx.com |
Management
|
Alan M. Garber
Independent Director |
|
Amit K. Sachdev
Chief Patient Officer & Executive Vice President |
|
Bruce I. Sachs
Lead Independent Director |
|
Carmen Bozic
Chief Medical Officer & EVP-Medical Affairs |
|
Catherine Rutten
Vice President-International & Government Affairs |
|
Charles F. Wagner
Chief Financial Officer & Executive Vice President |
|
David Matthew Altshuler
Chief Scientific Officer & EVP-Global Research |
|
Diana L. McKenzie
Independent Director |
|
Edward Morrow Atkinson
Chief Technical Operations Officer & Executive VP |
|
Jeffrey M. Leiden
Executive Chairman |
|
Jennifer Schneider
Independent Director |
|
Jonathan Prim Biller
Chief Legal Officer & Executive Vice President |
|
Joy Liu
Secretary, Senior Vice President & General Counsel |
|
Kristen C. Ambrose
Chief Accounting Officer & Senior Vice President |
|
Lloyd A. Carney
Independent Director |
|
Ludovic Fenaux
Senior VP-International Commercial Operations |
|
Mark Bunnage
Senior Vice President & Head-Research |
|
Michel Lagarde
Independent Director |
|
Mike Tirozzi
Senior VP, Chief Information & Data Officer |
|
Nancy A. Thornberry
Independent Director |
|
Nia Tatsis
Chief Regulatory & Quality Officer, Executive VP |
|
Nicole A. Gabreski
Associate Director-External Innovation |
|
Reshma Kewalramani
President, Chief Executive Officer & Director |
|
Sangeeta N. Bhatia
Independent Director |
|
Sean Daughtry
Senior Director-Analytical Sciences & Technology |
|
Stephanie Franklin
Chief Human Resources Officer & Senior VP |
|
Stuart A. Arbuckle
Chief Operating Officer & Executive Vice President |
|
Suketu P. Upadhyay
Independent Director |
|
Susie Lisa
Senior Vice President-Investor Relations |